Ilyang Pharmaceutical Co Ltd
KRX:007570
Relative Value
The Relative Value of one Ilyang Pharmaceutical Co Ltd stock under the Base Case scenario is 22 885.85 KRW. Compared to the current market price of 13 900 KRW, Ilyang Pharmaceutical Co Ltd is Undervalued by 39%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
Competitors Multiples
Ilyang Pharmaceutical Co Ltd Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
KR |
I
|
Ilyang Pharmaceutical Co Ltd
KRX:007570
|
249.8B KRW | 0.7 | -98.1 | 8.2 | 12.7 | |
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
726.1B USD | 20.2 | 118.3 | 57.9 | 65.9 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4.1T DKK | 16.6 | 45.4 | 33.9 | 37.1 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
364.3B USD | 4.3 | 9.5 | 11.7 | 15.2 | ||
US |
Merck & Co Inc
NYSE:MRK
|
325.9B USD | 5.3 | 141.3 | 35.2 | 57.5 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
189.8B GBP | 5 | 37.7 | 175 | 279.1 | ||
CH |
Novartis AG
SIX:NOVN
|
183.4B CHF | 3.4 | 11.5 | 8.8 | 12.8 | ||
CH |
Roche Holding AG
SIX:ROG
|
179.1B CHF | 3 | 15.6 | 8.9 | 10.5 | ||
US |
Pfizer Inc
NYSE:PFE
|
160.2B USD | 2.9 | -518.6 | 12.8 | 20.4 |